Navigation Links
Amsterdam Molecular Therapeutics Files Glybera® European Marketing Application for Re-examination
Date:7/7/2011

AMSTERDAM, July 7, 2011 /PRNewswire/ --


Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that it has filed a request for re-examination of the Marketing Authorisation Application for Glybera® with the European Medicines Agency. Glybera is a gene therapy for the genetic disorder lipoprotein lipase deficiency. The Company expects that the re-examination of the dossier will be completed by the end of 2011.

About Amsterdam Molecular Therapeutics

AMT is a world leader in the development of human gene based therapies. The company's lead product Glybera®, a gene therapy for lipoprotein lipase deficiency (LPLD), is currently under review by the European Medicines Agency (EMA). If approved, Glybera will be the first gene therapy product to be marketed in Europe. AMT also has a product pipeline of several gene therapy products in development for hemophilia B, Duchenne muscular dystrophy, acute intermittent porphyria, Parkinson's disease and SanfilippoB. Using adeno-associated viral (AAV) derived vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate probably the world's first stable and scalable AAV manufacturing platform. This proprietary platform can be applied to a large number of rare (orphan) diseases caused by one faulty gene and allows AMT to pursue its strategy of focusing on this sector of the industry.  AMT was founded in 1998 and is based in Amsterdam. Further information can be found at http://www.amtbiopharma.com.

Certain statements in this press release are "forward-looking statements" including those that refer to management's plans and expectations for future operations, prospects and financial condition. Words such as "st
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
2. Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy
3. Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
4. Amsterdam Molecular Therapeutics Reports Full Year Results 2009
5. The University of Amsterdam Joins the MetaMiner Metabolic Diseases Project
6. Amsterdam Molecular Therapeutics Reports Half Year Results 2009
7. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
8. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
9. Elsevier and Molecular Connections Develop Two New Applications on SciVerse Applications
10. Biochemist and Geneticist Ronald W. Davis Receives $500,000 Gruber Genetics Prize for Pioneering Work in the Development of Biotechnologies that Have Significantly Advanced the Fields of Molecular Genetics and Genomics
11. NIH grant ratchets up ASU research in molecular motors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2015)... pharmaceutical market is one of the most attractive in ... size, plus a growing economy and increasing government investment ... International. The Russian market is set to grow at ... growth estimates around 10-15% annually reaching an approximate market ... Green Cross Green Cross provides total healthcare ...
(Date:3/25/2015)... Optimal Research, LLC has been nominated as ... "Best Clinical Site or Trial Network". This ... selected as a nominee in this ViE award category ... distinction in 2014. The ViE awards were created to ... positive contributions of companies and individuals in the vaccine ...
(Date:3/25/2015)... March 25, 2015 Laboratory workers ... Balances and Analytical Balances to get best-performing features ... of weighing balances from the trusted brand include: ... increase your efficiency by providing a large ... samples. Weighing modes include parts counting, percent weighing, ...
(Date:3/25/2015)... An increase of awareness related to benefits ... food nutrients, regulatory changes and concerns related to consumer ... for natural astaxanthin over the past few years. Producers ... capacities to satisfy the rising demand. , The ... (used in nutraceuticals, aqua feed, food and beverages and ...
Breaking Biology Technology:Optimal Research Nominated 2015 Vaccine Industry Excellence (ViE) Award 2New Economical Top-Loading and Analytical Symmetry Balances from Cole-Parmer 2Global Astaxanthin Market to Reach Value of USD 1.1 billion by 2020, Expects Industry Experts in New Report Available at MarketPublishers.com 2
... Kan., Nov. 16, 2011 The Kansas Bioscience Authority ... ended June 30, and cumulative outcomes since the KBA,s ... investments, are reported annually based on information provided by ... full-time jobs created by bioscience companies in Kansas; ...
... Livestream Info ... http://thehill.com/video/in-the-news/193083-livestreaming-genetic-testing-briefing . , ... is redefining cancer treatment, and the pace of discovery promises ... conditions. That will be among the topics of discussion today ...
... 2011 Nektar Therapeutics (NASDAQ: NKTR ... a next-generation topoisomerase I inhibitor, at the 2011 ... being held in San Francisco, California.  The preclinical ... pegylated liposomal doxorubicin (PLD) in vivo has strong ...
Cached Biology Technology:Kansas Bioscience Authority Announces FY11 Outcomes of $207 Million 2Kansas Bioscience Authority Announces FY11 Outcomes of $207 Million 3Members of Congress, Cancer Experts Address Impact of Genetic Testing on Cancer 2NKTR-102 Demonstrates Synergistic Anti-Tumor Activity in Combination with Pegylated Liposomal Doxorubicin in Platinum-Resistant Ovarian Cancer 2NKTR-102 Demonstrates Synergistic Anti-Tumor Activity in Combination with Pegylated Liposomal Doxorubicin in Platinum-Resistant Ovarian Cancer 3NKTR-102 Demonstrates Synergistic Anti-Tumor Activity in Combination with Pegylated Liposomal Doxorubicin in Platinum-Resistant Ovarian Cancer 4NKTR-102 Demonstrates Synergistic Anti-Tumor Activity in Combination with Pegylated Liposomal Doxorubicin in Platinum-Resistant Ovarian Cancer 5NKTR-102 Demonstrates Synergistic Anti-Tumor Activity in Combination with Pegylated Liposomal Doxorubicin in Platinum-Resistant Ovarian Cancer 6
(Date:3/11/2015)... , March 11, 2015   The ... its platform to scientifically measure and harness music ... to real-time biometrics and objective measurements of physiology, ... music at scale in large populations. It is ... technologists and clinicians perform rigorous studies and accelerate ...
(Date:3/5/2015)... In Brazil , cloud computing ... these solutions and 42 percent planning to invest in them ... percent of the companies will be investing in these solutions ... companies in the region are currently opting for the private ... command significant attention in the coming years. This trend is ...
(Date:3/2/2015)... , March 2, 2015   Neurotechnology , ... today introduced the SentiGaze Software Development Kit ... create applications that use off-the-shelf webcams to track eye ... gazes at a monitor. Heatmaps can be used for ... effectiveness of online advertising. The SDK can also be ...
Breaking Biology News(10 mins):Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 2Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 4Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 2Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 3
... events, two comprehensive, collaborative projects that include the work ... Natural History will grace the covers of the journals ... Science, herpetologist and Associate Dean of Science Christopher Raxworthy ... more typical few keystone species, to determine a conservation ...
... be so old that dinosaurs once lumbered along its rim, ... Colorado at Boulder and the California Institute of Technology. ... show the Grand Canyon may have formed more than 55 ... million to 50 million years. The researchers gathered evidence ...
... the evolutionary history of animals indicates that Earth,s first ... from fossils and studies of living animals--was probably significantly ... which was funded by the National Science Foundation (NSF), ... issue of Nature. Using new high-powered technologies for analyzing ...
Cached Biology News:AMNH scientists grace Science & Nature covers 2AMNH scientists grace Science & Nature covers 3Grand Canyon may be as old as dinosaurs, says new study 2Grand Canyon may be as old as dinosaurs, says new study 3And the first animal on Earth was a... 2And the first animal on Earth was a... 3
Anti-Potassium Channel Kv2.2 Immunogen: Synthetic peptide from rat Kv2.2. Available Date: 38376...
Mouse monoclonal [1241] to Parainfluenza Virus type 2...
Mouse monoclonal [1C6/2] to Rad17 ( Abpromise for all tested applications). entrezGeneID: 5884 SwissProtID: Q9UPF5...
... contain a proprietary high-performance desalting resin, exclusive ... protein-recovery characteristics compared to other commercially available ... g/ml of protein can be processed, providing ... of salts and other small molecules ( ...
Biology Products: